Spero
Business Services · Massachusetts, United States · 11-50 Employees
View Company Info for Free
Overview
Headquarters
675 Massachusetts Ave Ste 14, Cambridge,...Phone Number
(857) 242-1600Website
www.sperotx.comRevenue
$43 MillionIndustry
ZI Rank: 1
Signal Type
Mar
Apr
May
Jun
Jul
Aug
ZI Rank
1
1
1
1
1
1
About Spero
Spero Therapeutics (Nasdaq: SPRO) is a Cambridge, MA-based biotech company. In mid-2026, it executed a major strategic pivot from infectious diseases to immunology and inflammation. This shift is anchored by SP001, a licensed Phase 2-ready anti-CD40L antibody targeting IgG4-related disease. Spero also secured FDA approval for Utebzi, the first oral carbapenem for urinary tract infections. Spero monetized these drug royalties to fund its new pipeline.Explore more
Spero Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Spero your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Click to see if Spero had a recent Job posting/layoffs
Website visits: Recent activity has been detected on your website
Funding: Get notified immidiatlly once Spero has new funding data
Check if Spero has recently received funding, and reach out quickly before it becomes old news!
Congratulate Masked Content for being promoted to Masked Content at Spero
Product Launch: Get notified when Spero launches new products
Earning: See what the market has to say on Spero recently announced quarterly report
Check out if Spero is spiking on competitors!
Spero, which may be a good buyer, showed buying intent in Masked Content Topic
Recommended Actions
Reach out to Masked Content who joined Spero as Masked Content
Find more new buyers
Company Profile Activity
Activity Insights
Spero is experiencing very low activity levels compared to other companies in the Business Services sector.
What does this means?
Spero is drawing exceptional interest within the Business Services industry, suggesting notable developments or strong market momentum, learn more about Spero.
Spero financials insights
Gather financial insights about Spero, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2026
Debt
$105M
Spero Tech Stack
A closer look at the technologies used by Spero
See more technologies
Most Recent Scoops
Funding
Funding
Earnings
Earnings, Finance
Earnings
Earnings, Finance
Earnings
Earnings, Finance
Earnings
Earnings
Spero News & Media
Spero Therapeutics to Present at H.C. Wainwright 28th Annual Global Investment Conference
CAMBRIDGE, Mass., Sept. 02, 2026 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a clinical-stage biopharmaceutical company focused on advancing next-generation medicines in immunology and inflammation, today announced that Esther Rajavelu, President and Chief Executive Officer, will present at the H.C. Wainwright 28th Annual Global Healthcare Conference, to be held in New York City, September 14th -16th, 2026. Spero's leadership team will also be available for one-on-one meetings a
Read more news
Top Business Services Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Frequently Asked Questions Regarding Spero
Sign Up For FreeTo access detailed company insights
Spero Therapeutics (Nasdaq: SPRO) is a Cambridge, MA-based biotech company. In mid-2026, it executed a major strategic pivot from infectious diseases to immunology and inflammation. This shift is anchored by SP001, a licensed Phase 2-ready anti-CD40L antibody targeting IgG4-related disease. Spero also secured FDA approval for Utebzi, the first oral... Read More
